NCT04900818 trial: what clinicians have said so far
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- NCT04900818 ↗
- Recruiting
- I-Mab Biopharma US Limited
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT04900818 (givastomig; givastomig plus nivolumab plus chemotherapy; givastomig plus chemotherapy in advanced or metastatic solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04900818 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Solid Tumor; Advanced Cancer; Metastatic Cancer; Gastric Cancer; Gastroesophageal Junction Carcinoma; Esophageal Adenocarcinoma; PDAC - Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancer (BTC)
- Interventions
- TJ033721 (givastomig); TJ033721 (givastomig) , nivolumab, chemotherapy; TJ033721 (givastomig), chemotherapy; TJ033721 (givastomig), durvalumab, chemotherapy
- Arms
- TJ033721 (givastomig) · Experimental
- TJ033721 (givastomig) in combination with nivolumab and chemotherapy · Experimental
- TJ033721 (givastomig) in combination chemotherapy · Experimental
- TJ033721 (givastomig) in combination with durvalumab and chemotherapy · Experimental
- Enrollment
- 330 (estimated)
- Primary outcomes
- Dose-limiting toxicities (DLTs)
- Incidence and severity of AEs
- Maximum tolerated or administered dose (MTD, MAD)
- Sponsor
- I-Mab Biopharma US Limited with Bristol-Myers Squibb
- Start
- Jun 29, 2021
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04900818 · updated Mar 5, 2026